GRAIL (NASDAQ:GRAL) Price Target Raised to $130.00

by · The Cerbat Gem

GRAIL (NASDAQ:GRAL – Free Report) had its target price boosted by Piper Sandler from $74.00 to $130.00 in a report released on Tuesday,Benzinga reports. The firm currently has a neutral rating on the stock.

A number of other research firms also recently commented on GRAL. Morgan Stanley boosted their price objective on shares of GRAIL from $60.00 to $120.00 and gave the stock an “equal weight” rating in a report on Monday, October 12th. Royal Bank Of Canada increased their target price on shares of GRAIL from $84.00 to $100.00 and gave the company a “sector perform” rating in a report on Thursday, November 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a report on Thursday, October 15th. Mizuho lifted their price target on shares of GRAIL from $65.00 to $100.00 and gave the company a “neutral” rating in a research report on Friday, September 25th. Finally, TD Cowen boosted their price target on GRAIL from $88.00 to $180.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Five equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, GRAIL has an average rating of “Hold” and a consensus target price of $128.80.

Read Our Latest Analysis on GRAIL

GRAIL Price Performance

GRAIL stock opened at $121.35 on Tuesday. GRAIL has a one year low of $41.50 and a one year high of $166.48. The business has a fifty day moving average of $120.75 and a two-hundred day moving average of $79.69.

GRAIL (NASDAQ:GRAL – Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported ($2.21) EPS for the quarter, topping the consensus estimate of ($2.45) by $0.24. GRAIL had a negative net margin of 243.80% and a negative return on equity of 16.13%. The company had revenue of $37.53 million for the quarter, compared to analyst estimates of $44.21 million. On average, analysts expect that GRAIL will post -9.11 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Joshua Ofman sold 61,452 shares of GRAIL stock in a transaction on Monday, September 21st. The stock was sold at an average price of $97.74, for a total transaction of $6,006,318.48. Following the completion of the transaction, the chief executive officer owned 362,271 shares of the company’s stock, valued at $35,408,367.54. The trade was a 14.50% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Andrew Partridge sold 7,873 shares of GRAIL stock in a transaction on Monday, October 5th. The stock was sold at an average price of $146.39, for a total value of $1,152,528.47. Following the transaction, the insider directly owned 155,865 shares of the company’s stock, valued at $22,817,077.35. This trade represents a 4.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 129,944 shares of company stock worth $14,832,805 over the last 90 days. 1.83% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On GRAIL

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GRAL. BlackRock Inc. grew its position in shares of GRAIL by 20.5% in the second quarter. BlackRock Inc. now owns 3,577,075 shares of the company’s stock valued at $244,207,000 after purchasing an additional 608,539 shares during the last quarter. State Street Corp raised its position in shares of GRAIL by 26.1% during the 2nd quarter. State Street Corp now owns 2,385,514 shares of the company’s stock worth $162,859,000 after purchasing an additional 493,621 shares during the last quarter. Primecap Management Co. CA acquired a new position in shares of GRAIL during the 2nd quarter worth approximately $148,836,000. Bank of America Corp DE lifted its stake in GRAIL by 29.0% in the 1st quarter. Bank of America Corp DE now owns 914,114 shares of the company’s stock valued at $47,241,000 after buying an additional 205,611 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in GRAIL by 88.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 408,650 shares of the company’s stock valued at $21,104,000 after buying an additional 191,857 shares in the last quarter.

GRAIL Company Profile

(Get Free Report)

GRAIL, Inc. is a healthcare company developing blood-based tests for the early detection of multiple cancers. Its approach analyzes patterns in cell-free DNA, including DNA methylation signals, to help identify a possible cancer signal and predict its origin in the body. GRAIL’s flagship product is Galleri, a multi-cancer early detection test intended for use alongside—not as a replacement for—recommended cancer screening. The company also conducts clinical research to evaluate the test and advance its early-detection technology.

Further Reading